Airway and Serum Biochemical Correlates of Refractory Neutrophilic Asthma

Abstract

Background

Despite the progress in diagnosis and management of asthma, many patients have poorly controlled or refractory asthma. The mechanism of this refractory asthma is not well understood.

Objective

Explore the relationship between neutrophils and other biomarkers of refractory asthma.

Method

Sixty subjects with refractory asthma (RA), 30 with non-refractory asthma (NRA) and 20 healthy subjects were enrolled. We performed a comprehensive characterization of these study subjects, which included laboratory and pulmonary function studies, chest CT, and bronchoscopy with bronchoalveolar lavage. We analyzed BAL and serum for a total of 244 biomolecules by multiplex assay and correlated them with the clinical and other laboratory parameters.

Results

RA was significantly different from NRA with regard to pulmonary function indices, bronchial basement membrane thickness, and BAL neutrophils and lymphocytes but not eosinophils. BAL neutrophils negatively and positively correlated with the forced vital capacity and age, respectively. Of the 244 biomolecules studied, 52 and 14 biomolecules from BAL and serum, respectively, were significantly different among the study groups. Thirteen of these 52 molecules correlated with BAL neutrophils. BAL from 40% of RA patients was positive for a pathogenic microbe. Infection-negative neutrophilic RA was associated with an increase in select biomarkers of inflammation in the serum suggesting the presence of systemic inflammation.

Conclusions

RA was associated with increased number of neutrophils and proneutrophilic biomolecules in the airways. Subclinical infection was present in 40% of RA patients, which likely contributed to neutrophilic inflammation. A subgroup of non-infected neutrophilic RA was associated with systemic inflammation.

http://www.jacionline.org/article/S0091-6749(17)30147-1/abstract

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: United Action for Allergy and Asthma https://t.co/Bssbmnu3cF, see more https://t.co/CpGiFuOOYd
1hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: United Action for Allergy and Asthma https://t.co/xdIbmmWD5j, see more https://t.co/jgCeENQuZt
3hreplyretweetfavorite
Interasma RT @ARIAGuideline: Emerging technologies for predictive medicine in chronic airway diseases... https://t.co/1uOqcIwQ1o
3hreplyretweetfavorite
Interasma RT @Aller_MD: “Global Market Study on AR: Immunotherapy Segment Projected to be the Fastest Growing Segment” https://t.co/FC1n10wV6o https:…
4hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: The Myth of Drug Expiration Dates - ProPublica https://t.co/8bS0FafKTF, see more https://t.co/jgCeENQuZt
4hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma